Professor of Biostatistics; Director of Medical Research, School of Public Health
Optimizing Engagement in Discovery of Molecular Evolution of Low-grade Glioma (OPTIMUM)
Who can enter the study?
Any person currently 21 years of age or older (regardless of age at LGG diagnosis) with an initial diagnosis of grade II/III glioma (i.e. oligodendroglioma, astrocytoma) and two or more surgeries for their glioma.
To collect data, we will use our technology platform Hugo. Hugo is able to collect data from multiple sources including your hospital medical record, pharmacy, and any “wearables” such as smartphones and Fitbits and then stores them in your own secure cloud-based account.
We will also develop an app called ARCHETYP to make it easier for glioma patients to learn about clinical trials.